Alvotech and Teva have received FDA clearance in the U.S. for their product SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab).

Eloxx Pharmaceuticals, Inc. announced recent developments in their programs for ELX-02 and ZKN-013, highlighting the Orphan Drug Designation awarded to ELX-02.

In the TOPAZ-1 Phase III trial, the combination of Imfinzi and chemotherapy increased the three-year overall survival rate by twofold in patients with advanced biliary tract cancer.

Neurona Therapeutics Reports Encouraging Results from Its NRTX-1001 Cell Therapy Study in Adults Suffering from Drug-resistant Focal Epilepsy at the 2024 AAN Annual Meeting.

TransCode Therapeutics has received FDA approval to start a Phase 1/2 clinical trial of TTX-MC138 in patients with advanced solid tumors.

Latest findings from Novartis on Fabhalta® (iptacopan) reveal a notable and statistically significant decrease in proteinuria by 38.3% compared to placebo in individuals suffering from IgA nephropathy (IgAN).

Marinus Pharmaceuticals, Inc. has declared that the independent Data Monitoring Committee has advised proceeding with the crucial Phase 3 RAISE trial.

NiKang Therapeutics has administered the initial dose to a patient in its Phase 1/1b trial of NKT3447, an oral drug targeting CDK2 that decreases Cyclin E levels.

Fresenius has declared through its subsidiary, Fresenius Kabi, the launch of Tyenne (tocilizumab-aazg) in the United States.

Arvinas has initiated a deal with Novartis that encompasses a worldwide licensing pact to advance and market their PROTAC® technology-based AR degrader ARV-766, aimed at prostate cancer therapies.

Alpine Immune Sciences Reports New Clinical Data for Povetacicept in IgA Nephropathy.

Macomics Discloses Pioneering Anti-Pan-LILRB Antibody Initiative, Showcasing Encouraging Preclinical Results at 2024 AACR Event.